 |
|
UT Southwestern urologists identify seven biomarkers that may help pinpoint prostate cancer recurrence
June 18, 2008A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, UT Southwestern Medical Center researchers have found.
In a study published in the June 15 issue of Clinical Cancer Research, UT Southwestern scientists identified a panel of seven biomarkers that can predict with 86 percent accuracy which prostate cancer patients will experience a recurrence and progression of the disease. Biomarkers are proteins circulating in a patient's blood that are specific to a disease.
Current risk assessment methods, which include stage and grade of cancer and the level of prostate-specific antigen, can predict prostate cancer recurrence with about 70 percent accuracy.
"There are several unresolved issues in the clinical and surgical management of prostate cancer, one of them being the identification of men who have insignificant cancers and can be followed, and another being the identification of men most likely to have spread of disease and early or late recurrence," said Dr. Claus Roehrborn, chairman of urology at UT Southwestern and one of the study's authors. "In the future, once we can reliably identify those patients, we may be able to offer additional treatment to counteract that risk and give those men a better chance for a permanent cure. The panel of biomarkers is an important step in this direction."
For nine years, Dr. Shahrokh Shariat, who is now a resident in urology at UT Southwestern and the study's lead author, has been collaborating with basic-science researchers and clinicians to find a comprehensive group of biomarkers associated with prostate cancer that could more accurately predict the biological behavior of the disease.
Using commonly available blood testing methods, Dr. Shariat and his team measured the levels of seven biomarkers in 423 patients who were subsequently surgically treated with a radical prostatectomy and bilateral lymphadenectomy.
Of the study participants, 75 had a recurrence of their cancer. All 75 had elevated levels of at least several of the seven biomarkers. Dr. Shariat's seven-biomarker model was able to accurately predict the risk for recurrence 86.6 percent of the time.
"We found that a combination of independent yet complementary markers may provide a more accurate prediction outcome compared to single markers," Dr. Shariat said. "This could help physicians provide individualized care and targeted therapy for patients. It will also allow us to design clinical trials to target these individual biomarkers."
Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men in the United States. Although prostate-removal surgery and radiation therapy have been successful in controlling the disease, up to 40 percent of patients experience a relapse.
"A prediction tool based on the biomarkers we tested could improve the accuracy of standard models and help doctors counsel patients better about their risk for prostate cancer recurrence and help to determine the course of treatment," Dr. Shariat said. "There is no doubt that we are approaching a time when use of proper biomarkers will help detect, monitor and manage the progression of this disease, as well as assist with therapeutic decisions."
The next step is to explore the role of these biomarkers in patients treated with other therapies, such as radiation, and patients with a different range of disease severity.
Currently, the seven-biomarker panel is being externally validated in a clinical trial at two medical institutions, one in the United States and the other in Europe.
Dr. Jose Karam, a resident in urology at UT Southwestern, was also involved in the study.
An international team of researchers from the University of Montreal; Vita-Salute University in Milan, Italy; and Baylor College of Medicine contributed to the research.
The University of Texas Southwestern Medical Center at Dallas
"There are several unresolved issues in the clinical and surgical management of prostate cancer, one of them being the identification of men who have insignificant cancers and can be followed, and another being the identification of men most likely to have spread of disease and early or late recurrence," said Dr. Claus Roehrborn, chairman of urology at UT Southwestern and one of the study's authors. "In the future, once we can reliably identify those patients, we may be able to offer additional treatment to counteract that risk and give those men a better chance for a permanent cure. The panel of biomarkers is an important step in this direction."
For nine years, Dr. Shahrokh Shariat, who is now a resident in urology at UT Southwestern and the study's lead author, has been collaborating with basic-science researchers and clinicians to find a comprehensive group of biomarkers associated with prostate cancer that could more accurately predict the biological behavior of the disease.
Using commonly available blood testing methods, Dr. Shariat and his team measured the levels of seven biomarkers in 423 patients who were subsequently surgically treated with a radical prostatectomy and bilateral lymphadenectomy.
Of the study participants, 75 had a recurrence of their cancer. All 75 had elevated levels of at least several of the seven biomarkers. Dr. Shariat's seven-biomarker model was able to accurately predict the risk for recurrence 86.6 percent of the time.
"We found that a combination of independent yet complementary markers may provide a more accurate prediction outcome compared to single markers," Dr. Shariat said. "This could help physicians provide individualized care and targeted therapy for patients. It will also allow us to design clinical trials to target these individual biomarkers."
Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men in the United States. Although prostate-removal surgery and radiation therapy have been successful in controlling the disease, up to 40 percent of patients experience a relapse.
"A prediction tool based on the biomarkers we tested could improve the accuracy of standard models and help doctors counsel patients better about their risk for prostate cancer recurrence and help to determine the course of treatment," Dr. Shariat said. "There is no doubt that we are approaching a time when use of proper biomarkers will help detect, monitor and manage the progression of this disease, as well as assist with therapeutic decisions."
The next step is to explore the role of these biomarkers in patients treated with other therapies, such as radiation, and patients with a different range of disease severity.
Currently, the seven-biomarker panel is being externally validated in a clinical trial at two medical institutions, one in the United States and the other in Europe.
Dr. Jose Karam, a resident in urology at UT Southwestern, was also involved in the study.
An international team of researchers from the University of Montreal; Vita-Salute University in Milan, Italy; and Baylor College of Medicine contributed to the research.
The University of Texas Southwestern Medical Center at Dallas
Biomarkers Current Events and Biomarkers News RSSHormone therapy associated with reduced colorectal cancer risk
The combination of estrogen plus progestin, which women stopped taking in droves following the news that it may increase their risk of breast cancer, may decrease their risk of colorectal cancer, according to a report published in the January issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research.
Using math to understand hep. C: Patterns paint picture of who will respond to treatment
Genetic patterns are like the tea leaves in the bottom of a cup for predicting which patients are likely to respond to medical therapy for life-threatening viruses such as hepatitis C, Saint Louis University researchers have discovered.
Biomarkers improve ischemic stroke prediction
Testing patient's blood for two proteins or biomarkers that occur when inflammation is present could help doctors identify which patients are more likely to have a stroke, said researchers at Baylor College of Medicine in Houston in a report that appears online in the journal Stroke.
Hubble finds carbon dioxide on an extrasolar planet
The NASA/ESA Hubble Space Telescope has discovered carbon dioxide in the atmosphere of a planet orbiting another star.
Biomarkers in blood could aid diagnosis of crippling, often fatal forms of malaria
Canadian researchers have identified protein biomarkers that shed new light on the development of two severe and debilitating forms of malaria.
Men with wives, significant others more likely to be screened for prostate cancer
Although the link between early screening and prostate cancer survival is well established, men are less likely to go for early screening unless they have a wife or significant other living with them.
Stanford blood scanner detects even faint indicators of cancer
A team led by Stanford researchers has developed a prototype blood scanner that can find cancer markers in the bloodstream in early stages of the disease, potentially allowing for earlier treatment and dramatically improved chances of survival.
Brain waves show sound processing abnormalities in autistic children
Abnormalities in auditory and language processing may be evaluated in children with autism spectrum disorder by using magnetoencephalography (MEG), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Understanding how oxidative stress impairs endothelial progenitor cell function
Although its been over a decade since endothelial progenitor cells or EPCs, cells that circulate in the blood repairing and replacing the cells that line blood vessels, were identified, the field is still evolving.
Bipolar disorder genes, pathways identified by Indiana University neuroscientists
Neuroscientists at the Indiana University School of Medicine have created the first comprehensive map of genes likely to be involved in bipolar disorder.
More Biomarkers Current Events and Biomarkers News Articles
 | Biomarkers: The 10 Keys to Prolonging Vitality by William Evans Exciting new evidence from the USDA Human Nutrition Research Center on Aging at Tufts University has demonstrated that the body's decline is due not to the passing of years but to the combined effects of inactivity, poor nutrition, and illness -- much of which can be controlled. This breakthrough study shows that regardless of your age or present physical condition, the aging process can be... |
 | Biomarkers: 10 Determinants of Aging You Can Control by William Evans, Irwin Rosenberg |
 | Biomarkers in Breast Cancer (Cancer Drug Discovery and Development) Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design... |
 | The Biomarker Guide: Volume 2, Biomarkers and Isotopes in Petroleum Systems and Earth History by K. E. Peters, C. C. Walters, J. M. Moldowan The second volume itemizes parameters used to genetically correlate petroleum and interpret thermal maturity and extent of biodegradation. It documents most known petroleum systems by geologic age throughout Earth... |
| Neuropsychiatric Biomarkers, Endophenotypes and Gene: Promises, Advances and Challenges: Volume II: Neuroanatomical and Neuroimaging Candidate Endophenotypes and Biomarkers Neuropsychiatric disorders such as schizophrenia, mood disorders, Alzheimer's disease, epilepsy, alcoholism, substance abuse and others are one of the most debilitating illnesses worldwide characterizing by the complexity of the causes, and lacking the laboratory tests that may promote diagnostic and prognostic procedures. Recent advances in neuroscience, genomic, genetic, proteomic and... | |
| Trial Design for Biomarkers, An Issue of Clinics in Laboratory Medicine (The Clinics: Internal Medicine) by Daniel Sargent | |
 | Biomarkers by S.V.S. Rana, Sung-Eun Lee |
| Statistical Design and Analysis of Biomarker Studies by Korn | |
 | Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships: Workshop Summary (Forum on Neuroscience and Nervous System Disorders) by National Research Council (U. S.) Biomarkers, or biological markers, are quantitative measurements that offer researchers and clinicians valuable insight into diagnosis, treatment and prognosis for many disorders and diseases. A major goal in neuroscience medical research is establishing biomarkers for disorders of the nervous system. Given the promising potential and necessity for neuroscience biomarkers, the Institute of... |
| Neuropsychiatric Biomarkers, Endophenotypes, and Genes: Promises, Advances, and Challenges Neuropsychiatric disorders such as schizophrenia, major depression, bipolar and anxiety disorders, Alzheimer's disease, epilepsy, alcoholism, substance abuse, and others are one of the most debilitating illnesses worldwide characterizing by the complexity of the causes, and lacking the laboratory tests that may promote diagnostic and prognostic procedures. Recent advances in neuroscience,... |
| © 2009 BrightSurf.com |